8-K: Structure Therapeutics Reports Strong Phase 2 Aleniglipron Data

Structure Therapeutics announced positive topline data from its Phase 2 ACCESS II trial and interim data from supplementary studies for its oral GLP-1 receptor agonist, aleniglipron, demonstrating significant weight loss and improved tolerability.

Summary

• Aleniglipron achieved clinically meaningful and statistically significant placebo-adjusted mean weight loss of 16.3% (39 lbs) at the 180 mg dose and 16.0% (37 lbs) at the 240 mg dose at 44 weeks in the Phase 2 ACCESS II study.
• In the ACCESS Open Label Extension (OLE) study, aleniglipron achieved continued weight loss from 36 weeks, up to 16.2% (40.5 lbs) with 120 mg at 56 weeks, with no evidence of weight loss plateau.
• Interim data from the body composition study showed a 6.8% weight loss after a median follow-up of 20 weeks (~30 mg titration step) with a 2.5 mg starting dose.
• The use of a 2.5 mg lower starting dose significantly reduced AE-related discontinuations during the titration phase, with overall AE-related discontinuation rates of 2.0% in the OLE and 3.4% in the body composition study.
• Aleniglipron demonstrated a compelling safety profile across more than 625 participants, with no cases of drug-induced liver injury, persistent liver enzyme elevations, or QTc prolongation.
• An End-of-Phase 2 meeting with the FDA is scheduled for Q2 2026 to finalize the Phase 3 design, with Phase 3 initiation anticipated in the second half of 2026.

Sentiment

Score: 9

Explanation: StockSavvy.ai views this as highly positive due to strong efficacy data, improved tolerability with dose adjustments, and a clean safety profile, positioning aleniglipron as a potential best-in-class oral GLP-1 for a massive market.

Positives

• Aleniglipron demonstrated the highest efficacy observed for an oral GLP-1RA to date, with placebo-adjusted mean weight loss of 16.3% (39 lbs) at 180 mg and 16.0% (37 lbs) at 240 mg at 44 weeks in ACCESS II.
• Efficacy is comparable to injectable GLP-1RAs, positioning aleniglipron as a potential best-in-class oral therapy for obesity.
• Continued weight loss up to 16.2% (40.5 lbs) was observed at 56 weeks in the ACCESS OLE study, with no evidence of weight loss plateau.
• Improved tolerability profile with a lower 2.5 mg starting dose, leading to significantly reduced AE-related discontinuations (2.0% in OLE, 3.4% in Body Composition study).
• Compelling safety profile with no drug-induced liver injury, persistent liver enzyme elevations, or QTc prolongation across all studies.
• High rates of participants achieving significant weight reduction: 93% achieved ≥10% and 61% achieved ≥15% body weight reduction at the 180 mg dose in ACCESS II.

Negatives

• The most common adverse events were gastrointestinal (GI)-related, such as nausea and vomiting, consistent with the GLP-1 receptor agonist class.
• Higher incidence of vomiting was observed in the 240 mg cohort compared to the 120 mg and 180 mg cohorts in the ACCESS II study post re-randomization.
• Topline results are based on preliminary analysis of key efficacy and safety data, which may change following a more comprehensive review.
• Reported efficacy and safety data are not based on head-to-head studies and may not be directly comparable to other oral or injectable GLP-1s due to differences in study design and participant characteristics.

Risks

• Topline results are based on preliminary analysis of key efficacy and safety data, and such data may change following a more comprehensive review of the clinical trial data.
• The preliminary nature of the results is due to the length of the study and sample size, and results from earlier clinical studies are not necessarily predictive of future results.
• Reported efficacy and safety data are not based on head-to-head studies and therefore may not be comparable to other oral or injectable GLP-1s due to differences in study design, participant characteristics, and how results are recorded.
• Aleniglipron is in clinical development, and even if regulatory approval is obtained, there are no guarantees that it will outperform other therapies in terms of efficacy or tolerability.
• Potential delays in the commencement, enrollment, and completion of the planned Phase 3 clinical program and other clinical studies, possibly as a result of feedback from the End-of-Phase 2 meeting with the FDA or otherwise.
• The company's ability to advance aleniglipron and its other therapeutic candidates, obtain regulatory approval, and ultimately commercialize them.
• Competitive products or approaches may limit the commercial value of the company's product candidates.
• The company's ability to fund development activities and achieve development goals.
• Reliance on third parties, including clinical research organizations, manufacturers, suppliers, and collaborators, over which the company may not always have full control.
• General geopolitical and macroeconomic conditions, including as a result of tariffs and various global conflicts.
• The company's ability to protect its intellectual property.

Future Outlook

Structure Therapeutics plans to advance aleniglipron into Phase 3 clinical development, with an End-of-Phase 2 meeting with the FDA scheduled for Q2 2026 to finalize the trial design. The Phase 3 program is anticipated to initiate in the second half of 2026, designed with a 2.5 mg starting titration dose and evaluating multiple doses up to 240 mg. The company believes aleniglipron has the potential to be a best-in-class oral small molecule GLP-1 and a backbone therapy for obesity, with potential for expansion beyond obesity into chronic kidney disease, metabolic associated steatohepatitis (MASH), heart failure, sleep apnea, type 2 diabetes mellitus, osteoarthritis, and addiction.

Management Comments

• "The totality of efficacy and tolerability data across the Phase 2 program continue to demonstrate clear differentiation of aleniglipron, with the highest weight loss observed for an oral GLP-1RA to date and a safety profile appropriate for chronic use in a disease that impacts millions of people." Raymond Stevens, Ph.D., CEO of Structure Therapeutics.
• "The consistent weight loss observed across multiple studies to date reaffirms aleniglipron’s potential to be a best-in-class oral GLP-1, with injectable-like efficacy that could become a backbone oral small molecule therapy for obesity." Raymond Stevens, Ph.D., CEO of Structure Therapeutics.
• "The weight-lowering data from these ACCESS studies, without apparent plateau by Week 56, are encouraging—particularly the weight loss from baseline of up to -15.3% vs +1.1% at 180 mg in ACCESS II that hopefully will be confirmed in larger, longer-term studies." Julio Rosenstock, MD, Chair of the ACCESS program Steering Committee.
• "In addition, the tolerability profile of starting at a low dose of 2.5 mg and the slow titration, positions the program ready for Phase 3 studies." Julio Rosenstock, MD, Chair of the ACCESS program Steering Committee.

Industry Context

StockSavvy.ai notes that aleniglipron's reported efficacy, achieving up to 16.3% placebo-adjusted weight loss, positions it as a leading oral GLP-1RA, potentially comparable to injectable GLP-1RAs. This could address the significant unmet need for accessible obesity treatments, as current injectable GLP-1s reach less than 5% of the addressable US market, which includes over 100 million people with obesity or overweight conditions. The company's focus on oral small molecules aims to overcome scalability limitations of traditional biologic and peptide therapies, targeting a global market of over 1 billion people with overweight and obesity.

Comparison to Industry Standards

• Aleniglipron's 16.3% placebo-adjusted mean weight loss at 44 weeks (180 mg dose) is stated to be the "highest efficacy among oral GLP-1RAs" and to have "comparable efficacy to injectable GLP1-RAs."
• The filing explicitly states that the reported efficacy and safety data are not based on head-to-head studies and therefore may not be comparable to other oral or injectable GLP-1s due to differences in study design, participant characteristics, and how companies quantify or qualify eligibility criteria and record results.

Stakeholder Impact

• Shareholders: Positive impact due to strong clinical data, potential for a best-in-class oral obesity drug, and advancement to Phase 3, which could increase company valuation and future revenue potential.
• Patients (living with obesity/overweight): Potential for a highly effective, accessible, and well-tolerated oral treatment option, addressing a significant unmet medical need.
• Healthcare Providers: New, potentially superior oral treatment option for managing obesity and related comorbidities.
• Competitors: Increased competitive pressure in the GLP-1 receptor agonist market, particularly for oral formulations.

Next Steps

• End-of-Phase 2 meeting with the United States Food and Drug Administration (FDA) in Q2 2026 to finalize Phase 3 design.
• Initiation of the Phase 3 program in the second half of 2026.
• Ongoing ACCESS OLE, ACCESS II Extension, Body Composition, SWITCH, and T2DM studies with data anticipated in 2H 2026.
• Phase 1 initiation anticipated Q4 2026 for ACCG-3535 (DACRA).

Key Dates

Recommendation

The filing presents exceptionally strong Phase 2 data for aleniglipron, demonstrating high efficacy (up to 16.3% weight loss) comparable to injectable GLP-1s, coupled with an improved tolerability profile through a lower starting dose and a clean safety record. This positions the drug as a potential best-in-class oral GLP-1, addressing a massive and underserved global market. The clear path to Phase 3 initiation in 2H 2026, following a Q2 2026 FDA meeting, significantly de-risks the development pathway and indicates strong commercial potential. These results are highly positive and suggest substantial future growth for Structure Therapeutics.

Keywords

Aleniglipron, GLP-1 receptor agonist, obesity, weight loss, Phase 2 clinical trial, ACCESS II, oral small molecule, biopharmaceutical, metabolic diseases, drug development, FDA, clinical data, GPCR